Advertisement Bayer HealthCare and Amerinet extend contrast media agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bayer HealthCare and Amerinet extend contrast media agreement

Bayer HealthCare Pharmaceuticals has received a two-year contract from Amerinet, to make Magnevist injection and Ultravist injection available to members of the Amerinet network.

The agreement is effective March 1, 2008 through 2010. It covers Magnevist in multiple presentations, including five, 10, 15 and 20mL single-dose vials, 50 and 100mL pharmacy bulk packages, and 10, 15 and 20mL pre-filled syringes of Magnevist. Ultravist will be available in four concentrations (150, 240, 300 and 370mgI) and in a variety of product presentations, including 500mL pharmacy bulk packages for the 300mgI and 370mgI concentrations.

Douglas Stefanelli, vice president and general manager, diagnostic imaging, Bayer HealthCare Pharmaceuticals, said: “We are pleased to continue our long-standing relationship with Amerinet and remain committed to providing its members with the high-quality, cost-effective products they need to serve their patient community.”